Evidence map›Paper›PMID 35655391›Full record

ArticleJournal of medical virology2022

Antibody response three months after SARS-CoV-2 infection.

Efdal Oktay Gültekin, Onur Gültekin, Arzu Coskun, Tiince Aksak

Open access · greenAbstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Efdal Oktay GültekinDepartment of Medical Services and Techniques, Toros Unıversity, Mersin, Turkey.ORCID 0000-0002-0962-152X
Onur GültekinTarsus State Hospital, Infectious Diseases, and Clinical Microbiology, Mersin, Turkey.ORCID 0000-0003-3444-9044
Arzu CoskunDepartment of Medical Services and Techniques, Toros Unıversity, Mersin, Turkey.ORCID 0000-0003-4771-1558
Tiince AksakDepartment of Medical Services and Techniques, Toros Unıversity, Mersin, Turkey.ORCID 0000-0001-7841-8456
Toros University · TRTarsus University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. In our study, it was aimed to determine the antibody levels in the third month after the COVID-19 infection and the symptoms that continued until the third month from the onset of the infection. One hundred people who applied to Tarsus State Hospital with the suspicion of COVID-19 and were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by real-time reverse transcriptase-polymerase chain reaction were included. We collected serum samples from individuals, who were 3 months postinfection, and tested them in anti-SARS-CoV-2 Quanti-Vac ELISA IgG kit coated with recombinant S1 antigen for testing SARS-CoV-2 antibodies. Antibody levels were found to be higher in those aged ≥55 years, nonsmokers, those with comorbidities, and those who were hospitalized. The four most common symptoms that individuals initially encounter; are weakness, muscle and joint pain, loss of taste and smell, and cough. In 3 months after COVID-19 infection, the most common four symptoms are; muscle and joint pain, insomnia, fatigue, and other problems were determined. In conclusion; more research is needed to determine threshold levels of serum antibodies that could prevent reinfection of SARS-CoV-2.

Indexed as

COVID-19Antibodies, ViralAntibody FormationArthralgiaHumansImmunoglobulin GPandemicsSARS-CoV-2Antibodies, ViralImmunoglobulin Gimmune responsesimmunoglobulininfectionSARS coronavirusvirus classification

Identifiers

PMID35655391
PMCPMC9347927
OpenAlexW4282034757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.